Mereo BioPharma Group Balance Sheet Health
Financial Health criteria checks 6/6
Mereo BioPharma Group has a total shareholder equity of $50.5M and total debt of $4.4M, which brings its debt-to-equity ratio to 8.7%. Its total assets and total liabilities are $66.5M and $16.0M respectively.
Key information
8.7%
Debt to equity ratio
US$4.39m
Debt
Interest coverage ratio | n/a |
Cash | US$57.42m |
Equity | US$50.54m |
Total liabilities | US$15.96m |
Total assets | US$66.50m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: MAH0's short term assets ($63.8M) exceed its short term liabilities ($9.5M).
Long Term Liabilities: MAH0's short term assets ($63.8M) exceed its long term liabilities ($6.5M).
Debt to Equity History and Analysis
Debt Level: MAH0 has more cash than its total debt.
Reducing Debt: MAH0's debt to equity ratio has reduced from 65.6% to 8.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: MAH0 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: MAH0 has sufficient cash runway for 2.4 years if free cash flow continues to grow at historical rates of 8% each year.